Edgewise Therapeutics is projected to post a Q3 2026 loss of $0.55 per share on revenue of $119.23 million, with its current stock price of $37.68 trading below the $55.43 analyst target.
Investors are primarily focused on the strategic pipeline reorganization following the massive $2.65 billion divestiture of the company's muscular dystrophy franchise to Servier in July 2026.
The market is awaiting clinical timelines for the lead cardiovascular candidate, EDG-7500, as it enters Phase 3 development for hypertrophic cardiomyopathy.
With a balance sheet recently bolstered by a $1.55 billion upfront payment from the asset sale, analysts will scrutinize management’s plan to accelerate the cardiac sarcomere modulator portfolio and extend its multi-year cash runway.